| Issuer | % of Class | Filed | ||||
|---|---|---|---|---|---|---|
| Schedule 13D · 1 security · may seek to influence control | ||||||
|
BridgeBio Oncology Therapeutics, Inc.
13D
BBOT · 107924102
|
17.5% |
8/18/2025
Event 8/11/2025
|
||||
| BridgeBio Pharma LLC | 17.5% | |||||
| BridgeBio Pharma, Inc. | 17.5% | |||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.